Pappas Ventures names Pat Gage to scientific advisory board

Monday, July 9, 2012 04:56 PM

Pappas Ventures, a life sciences investor based in Durham, N.C., has appointed L. Patrick Gage, PhD, to the company's scientific advisory board.

Gage has extensive experience in the biotech and pharmaceutical industry, overseeing the development of more than a dozen marketed biologics and vaccines, as well as several small molecule drugs. During his 18-year career at Hoffmann-La Roche, he held several leadership roles in research management, including service as vice president of exploratory research. Gage then joined Genetics Institute and ultimately served as president after Wyeth (now Pfizer) acquired the company. He was then named president of Wyeth Research, taking responsibility for global pharmaceutical and vaccine R&D, as well as global biopharmaceutical manufacturing.

Gage also founded enGage Biotech Consulting in 2003 to focus on guiding the development of new biopharmaceutical products and companies. In addition to his consulting work, he currently serves as chairman of Cytokinetics and chairman of Tetraphase Pharmaceuticals. He has previously served as chairman for PDL BioPharma and Adnexus Therapeutics.

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs